Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized placebo-controlled dose-ranging study of brivekimig in moderate to severe hidradenitis suppurativa
MOH_2025-11-24_015491Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Nov 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of brivekimig in hidradenitis suppurativa (HS) (4 arms), sponsored by Sanofi. Primary endpoint: HiSCR75 at primary efficacy assessment. Started Nov 2025; status: recruiting.
02
Drugs
brivekimig
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on MOH_2025-11-24_015491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-24_015491.